Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07360080 · ClinicalTrials.gov registry record
Long-Term Outcomes of Teplizumab in Routine Clinical Care
A clinical trial, sponsored by Sanofi.
- Recruiting
- Registry status
- 1,000
- Enrollment target
NCT07360080: Recruiting study, sponsored by Sanofi.
NCT07360080 is a clinical trial that is actively recruiting participants, run by Sanofi. The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07360080 is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
Study Summary
This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across multiple sites. Additionally, patient-reported outcomes (PROs) will be evaluated to further assess the treatment's impact on participant's quality of life including emotional and psychosocial aspects associated with T1D. This approach will provide a more comprehensive understanding of how the treatment performs over time and across diverse patient populations, providing valuable insights into the sustained effects of teplizumab and offering a real world picture of its impact on the long-term management of T1D.
Interventions
- DRUG Teplizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2026-03-19 |
| Est. Completion | 2035-10-29 |
What NCT07360080 shows while recruiting
NCT07360080 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Teplizumab is the first listed.
NCT07360080 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07360080 about?
NCT07360080 is a clinical study titled "Long-Term Outcomes of Teplizumab in Routine Clinical Care". This is an observational, prospective cohort study designed to evaluate the outcomes after teplizumab treatment in participants with Stage 2 Type 1 Diabetes (T1D) for delaying the onset of Stage 3 T1D. The study will monitor participants receiving teplizumab as part of routine clinical care across m...
What is the current status of trial NCT07360080?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2026-03-19. Estimated completion is 2035-10-29.
What interventions are being tested in trial NCT07360080?
The interventions under investigation include: Teplizumab (DRUG).
Who is sponsoring clinical trial NCT07360080?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI